Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia
NCT02932605
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
Placebo
DRUG:
Cannabidiol
Sponsor
UMC Utrecht